Skip to main content

Glenn Jay Jaffe

Robert Machemer M.D. Distinguished Professor of Ophthalmology
Ophthalmology, Vitreoretinal Diseases & Surgery
Box 3802 Med Ctr, Durham, NC 27710
Duke Eye Center, 2351 Erwin Ro, Durham, NC 27710

Selected Grants


Ocular Therapeutix DRC Ph 3 study in subjects with nAMD_OTX-TKI-2023

ResearchPrincipal Investigator · Awarded by Ocular Therapeutix Inc · 2023 - 2027

NAC Attack, a phase-3, multicenter, randomized, placebo-controlled trial with retinitis pigmentosa: OCT Reading Center

Clinical TrialPrincipal Investigator · Awarded by National Institutes of Health · 2022 - 2027

A Multicenter Study to Determine the Safety and Efficacy of NT-501 Utilizing the Medica Membrane in Macular Telangiectasia Type 2

ResearchPrincipal Investigator · Awarded by Neurotech Pharmaceuticals, Inc. · 2024 - 2025

Learning-based 3D modeling of AMD to assess disease progression and response to treatment

ResearchCo Investigator · Awarded by National Institutes of Health · 2023 - 2025

Rate of Progression of PCDH15-Related Retinal Degeneration in Usher Syndrome 1F (RUSH1F)

ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2021 - 2025

Rate of Progression in EYS-Related Retinal Degeneration (PRO-EYS)

ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2019 - 2025

Rate of Progression in USH2A Related Retinal Degeneration (RUSH2A)

ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2017 - 2025

Diabetic Retinopathy Clinical Research Network (DRCR.net)

ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2010 - 2024

FFB DRC Gyrate Atrophy Ocular and Systemic Study (GYROS)

ResearchPrincipal Investigator · Awarded by Jaeb Center For Health Research · 2022 - 2024

Evaluation of KPI-012's protective effects on RPE cells

ResearchPrincipal Investigator · Awarded by Combangio, Inc. · 2022 - 2023

LMRI DRC Phase 3 Clinical Trial of CNTF for MacTel Type 2-NTMT-03

ResearchPrincipal Investigator · Awarded by The Lowy Medical Research Institute · 2017 - 2023

Evaluation of the Heidelberg Engineering SPECTRALIS with Flex Module for In-vivo Imaging in the Supine Position

ResearchPrincipal Investigator · Awarded by Heidelberg Engineering · 2020 - 2022

Novartis DRC HAWK Centralized Imaging and Adjudication services, RTH258A/C1001502/I150 RTH258A2301

ResearchPrincipal Investigator · Awarded by Novartis Pharma AG · 2020 - 2021

Kato DRC Safety and Treatment Benefit of RESOLV ER¿ in Subjects with Mild to Moderate Non-Proliferative Diabetic Retinopathy

ResearchPrincipal Investigator · Awarded by Kato Pharmaceuticals, Inc · 2019 - 2021

LMRI DRC MacTel Phase II

Clinical TrialPrincipal Investigator · Awarded by The Lowy Medical Research Institute · 2013 - 2021

Evaluation of retinal cavitations in macular telangiectasia type 2 and response to ciliary neutrophic factor (CNTF)

FellowshipPrincipal Investigator · Awarded by VitreoRetinal Surgery Foundation · 2018 - 2020

DRC Editas Natural History Study of CEP290-Related Retinal Degeneration

ResearchPrincipal Investigator · Awarded by Editas Medicine Inc. · 2018 - 2020

Macular Edema Treatment Trials Associated with MUST (META-MUST)

Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2016 - 2020

pSivida PSV-FAI-001 Duke as Site

Clinical TrialPrincipal Investigator · Awarded by pSivida Corporation · 2013 - 2019

SciFluor DRC Wet AMD study

ResearchPrincipal Investigator · Awarded by SciFluor Life Sciences · 2018 - 2019

Computer Aided Classification of Diabetic Macular Edema

ResearchCollaborator · Awarded by National Institutes of Health · 2012 - 2018

ThromboGenics DRC OASIS study - provide raw images

ResearchPrincipal Investigator · Awarded by ThromboGenics Inc · 2017 - 2018

UPenn - NEI Follow-up Study: Comparison of AMD Treatment Trials (CATT) YR3

ResearchPrincipal Investigator · Awarded by University of Pennsylvania · 2013 - 2017

Neurotech DRC NT-503 (GEN 3)

Clinical TrialPrincipal Investigator · Awarded by Neurotech USA, Inc. · 2014 - 2017

Competitive Renewal for Multicenter Uveitis Steroid Treatment (MUST) Trial

Clinical TrialPrincipal Investigator · Awarded by Johns Hopkins University · 2009 - 2017

River Vision DRC DME

ResearchPrincipal Investigator · Awarded by River Vision Development Corporation · 2014 - 2017

Alcon DRC OVID II RTH255-P001

ResearchPrincipal Investigator · Awarded by Alcon Research, Inc. · 2015 - 2017

Coordinating Center for the Comparison of AMD Treatments Trials

ResearchCo Investigator · Awarded by University of Pennsylvania · 2014 - 2015

Comparison of AMD Treatment Trials-OCT Reading Center

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2006 - 2013

CATT OCT Reading Center

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 2009 - 2011

Cytokine Modulation in Proliferative Vitreoretinopathy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 2006

Cytokine Modulation In Proleferative Vitreoretinopathy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1997 - 1999

Cytokine Modulation In Proliferative Vitreoretinopathy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1996 - 1996

Cytokine Modulation In Proliferative Vtreoretinopathy

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1992 - 1996

Modulation Of Na+K+ Atpase In Retinal Detachment

ResearchPrincipal Investigator · Awarded by National Institutes of Health · 1989 - 1990

External Relationships


  • 4D Molecular Therapeutics
  • Annexon Biosciences, Inc.
  • BlueRock Therapeutics
  • EyePoint
  • Genentech Roche
  • 4D Molecular Therapeutics
  • Annexon Biosciences, Inc.
  • BlueRock Therapeutics
  • EyePoint
  • Genentech Roche
  • Kriya Therapeutiucs
  • Neurotech
  • Ocular Therapeutix Inc.
  • Regeneron Pharmaceuticals

This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.